Central Trust Company’s Fate Therapeutics FATE Stock Holding History

Central Trust Company’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4	Closed	–	–	1336
2022 Q2	$0	Hold	4	–	–	﹤0.01%	1389
2022 Q1	$0	Buy	+4	New	+$155	﹤0.01%	1392

Other funds holding FATE

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Central Trust Company's FATE Position: Q3 2022 in Review

Central Trust Company sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 4 shares.

Central Trust Company first reported a position in FATE in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

Central Trust Company reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
Central Trust Company sold 4 Fate Therapeutics shares in Q3 2022.
Central Trust Company first reported a position in Fate Therapeutics in Q1 2022 and held it in 2 quarters.
Central Trust Company's Fate Therapeutics position peaked at $0 in Q2 2022.
239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Central Trust Company's 13F filing for Q3 2022, filed 3 Nov 2022.